Nathan Coussens
Scientific Director, Molecular Pharmacology Laboratory, Frederick National Laboratory for Cancer Research
Nathan Coussens is listed as Scientific Director, Molecular Pharmacology Laboratory, Frederick National Laboratory for Cancer Research. Nathan is scheduled to speak at SLAS 2027 International Conference & Exhibition on 30 January 2027.
Compiled from published conference agendas; not yet confirmed by Nathan. Is this you? Claim this profile.
About
Nathan P. Coussens, Ph.D., is scientific director of the Molecular Pharmacology Laboratory (MPL) at the Frederick National Laboratory for Cancer Research (FNLCR). The MPL evaluates cancer therapeutics using hundreds of human tumor models, including patient-derived organoids, and contributes to the characterization and standardization of normal tissue organoids within the National Institutes of Health (NIH) Standardized Organoid Modeling Center. Previously, Dr. Coussens was a senior research scientist at the National Center for Advancing Translational Sciences, where he developed biochemical and cell-based assays for high-throughput screening to identify and characterize therapeutic leads for rare and neglected diseases. He is a co-inventor on three patents for experimental cancer therapeutics. Dr. Coussens serves on the FNLCR Scientific Standards Hub, which promotes rigor and reproducibility in biomedical research, and the SLAS Technology editorial board. He is also an associate editor
Upcoming
SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027
- Assay Guidance Workshop for High-Throughput Screening and Lead Discovery Speaker · 30 January 2027
Spoke alongside
People who have shared a session with Nathan at events on B2DB.
- Benjamin Bader Director / Head of Screening · Nuvisan 1 shared session
- Jayme Dahlin Medical Director, Clinical Development · Oruka Therapeutics 1 shared session
- Joe Trask Life Sciences Segment Manager, NA · Revvity 1 shared session
- Michelle Arkin Professor, Pharm Chem; co-Director, Small Molecule Discovery Center · University of California - San Francisco 1 shared session
- Sarine Markossian Editor-in-Chief, Assay Guidance Manual (AGM) and Lead, AGM Translational Science Resources Program · NCATS/NIH 1 shared session
- Stefan Grotegut Executive Director, High-Throughput Screening · Eli Lilly and Company 1 shared session
- Terry Riss Scientific Ambassador · Promega Corporation 1 shared session
- Thomas D.Y. Chung Director, Translational Programs Outreach · Sanford Burnham Prebys Medical Discovery Institute 1 shared session